Evicenter
Dupixent (dupilumab) in Atopic dermatitis
Manufacturer
sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.
Prescribing information
Dupixent (opens in a new tab)
Questions
76
Last updated

All questions

Real-world evidence: Dupixent (dupilumab) in atopic dermatitis

3 questions · 1 source

Real-world evidence

What itch results has Dupixent shown in real-world use (PROSE registry)?

What skin improvement has Dupixent shown at 4 years of real-world use?

How many patients stay on Dupixent long term for atopic dermatitis (real-world persistence)?

“RELIEVE-AD: RELIEVE-AD is a single-arm, prospective, observational study in patients with moderate-to-severe AD enrolled in DUPIXENT MyWay® prior to initiating treatment with DUPIXENT. Patients completed multiple surveys over 60 months. At Month 60, participants that responded to the survey at Month 33 and/or Month 48 were recontacted for Month 60 follow-up. Limitations of analysis: This patient population was self-selected; those who maintain long-term efficacy and safety may be more likely to participate in such surveys. Similarly, patients were recruited through a DUPIXENT patient support program, which may influence patient perceptions of treatment benefit.4,6 IBM MARKETSCAN: From IBM MarketScan Commercial and Medicare supplemental databases, 1963 adults were identified who initiated DUPIXENT between March 28, 2017, and March 31, 2018, and followed until September 30, 2018, or disenrollment. Patients received a mean of 8.6 DUPIXENT dispensations from initiation to first discontinuation. Limitations of analysis: Kaplan-Meier analysis was used to estimate persistence at 6 and 12 months, assuming a 14-day injection frequency. Limitations of this study may be the potential misclassification of patients in claims-based analyses that rely on International Classification of Disease (ICD) diagnostic codes for population identification. Study included only early initiators of DUPIXENT, which likely reflects more severe patients, potentially reducing generalizability since persistence may be different in a more diverse population of patients who initiate DUPIXENT. Duration of treatment and persistence was based on assumptions about whether and how patients take their treatment, and such assumptions may result in misclassification that could potentially over- or underestimate persistence.5” (opens the source at this quote in a new tab)